1-7 of 7
Domingo Domenech Eva
Close
Sort by
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9399–9401.
https://doi.org/10.1182/blood-2022-156576
Published: 2022
Journal Articles

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Domingo Domenech Eva, Fina Climent, Eva Gonzalez Barca, Eugenia de Lama, Maria Martinez Iniesta, Monica Calaf, Clara Montane, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Esmeralda de la Banda, Laura Arregui, Villanueva Alberto, Anna Sureda, Lourdes Farre
Journal: Blood
Blood (2022) 140 (Supplement 1): 8829–8830.
https://doi.org/10.1182/blood-2022-164848
Published: 2022
Journal Articles

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Domingo Domenech Eva, Marta Bellver, German Ferrer, Eva Gonzalez Barca, Itziar Carro, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Carmen Aguilera, Montserrat Alemany, Inmaculada Peiro, Anna Sureda, Roser Velasco
Journal: Blood
Blood (2022) 140 (Supplement 1): 9420–9421.
https://doi.org/10.1182/blood-2022-165345
Published: 2022
Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper
Journal: Blood
Blood (2021) 138 (Supplement 1): 135.
https://doi.org/10.1182/blood-2021-145124
Published: 2021
Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2459.
https://doi.org/10.1182/blood-2021-150200
Published: 2021
Journal Articles

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Domingo Domenech Eva, Juan-Manuel Sancho, Eva González-Barca, Nicholas Kelleher, Marta Rodriguez-Luaces, Jordina Rovira Sole, Silvia Verdesoto, Maite Encuentra, Damir Blazevic, Ana C Oliveira, Lourdes Escoda, Josep-Maria Ribera, Anna Sureda
Journal: Blood
Blood (2021) 138 (Supplement 1): 4543.
https://doi.org/10.1182/blood-2021-149506
Published: 2021
Journal Articles

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Dolores Caballero, Ranjana Advani, Raquel de Oña, Ana Marin Niebla, María José Terol, Domingo Domenech Eva, Nawal Bendris, Julie Mackey Ahsan, Mollie Leoni, Francine M. Foss
Journal: Blood
Blood (2021) 138 (Supplement 1): 621.
https://doi.org/10.1182/blood-2021-147279
Published: 2021